Zevra Therapeutics Inc
ZVRA11.110USD
0.000
Market hours （ET）Quotes delayed by 15 min
607.49MMarket Cap
LossP/E TTM
More Details of Zevra Therapeutics Inc Company
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Company Info
Ticker SymbolZVRA
Company nameZevra Therapeutics Inc
IPO dateApr 16, 2015
CEOMr. Neil F. Mcfarlane
Number of employees59
Security typeOrdinary Share
Fiscal year-endApr 16
Address1180 Celebration Boulevard
CityCELEBRATION
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code34747
Phone13219393416
Websitehttps://zevra.com/
Ticker SymbolZVRA
IPO dateApr 16, 2015
CEOMr. Neil F. Mcfarlane
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
23.61M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
Shareholders
Shareholders
Proportion
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.22%
Investment Advisor
22.55%
Investment Advisor/Hedge Fund
14.58%
Research Firm
1.43%
Private Equity
1.25%
Individual Investor
0.71%
Venture Capital
0.33%
Bank and Trust
0.11%
Pension Fund
0.06%
Other
34.76%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
239
35.69M
65.27%
-2.27M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
2023Q1
207
10.52M
30.95%
-2.74M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Woodline Partners LP
4.62M
8.44%
+476.03K
+11.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.78M
6.92%
+18.09K
+0.48%
Mar 31, 2025
Adage Capital Management, L.P.
3.62M
6.62%
-32.00K
-0.88%
Mar 31, 2025
The Vanguard Group, Inc.
2.83M
5.17%
+1.63K
+0.06%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.19M
4%
-15.70K
-0.71%
Mar 31, 2025
Nantahala Capital Management, LLC
1.47M
2.69%
-868.40K
-37.11%
Mar 31, 2025
Altium Capital Management LP
1.29M
2.35%
-562.67K
-30.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.23M
2.26%
+44.99K
+3.79%
Mar 31, 2025
683 Capital Management LLC
1.23M
2.24%
--
--
Mar 31, 2025
Rubric Capital Management LP
1.22M
2.23%
+601.61K
+97.64%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Simplify Propel Opportunities ETF
1.92%
iShares Neuroscience and Healthcare ETF
1.17%
SPDR S&P Pharmaceuticals ETF
0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.35%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
View more
Simplify Propel Opportunities ETF
Proportion1.92%
iShares Neuroscience and Healthcare ETF
Proportion1.17%
SPDR S&P Pharmaceuticals ETF
Proportion0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.35%
iShares Micro-Cap ETF
Proportion0.11%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
